Handok and the global biopharmaceutical company Sobi have officially launched their joint venture, “Sobi-Handok.” The official inauguration ceremony for Sobi-Handok was held on April 17th at Handok Tower in Yeoksam-dong, Seoul, attended by Handok Chairman Kim Young-jin, Sobi CEO Guido Oelkers, and Sobi International Vice President Norbert Oppitz.

The joint venture, established with a 49 to 51 equity ratio between Handok and Sobi for the rare disease business, was completed in March. Gerhard Passet, Sobi’s Asia Pacific GM and Vice President with extensive experience in the global rare disease business, will serve as the representative of Sobi-Handok.

Sobi-Handok plans to continuously introduce Sobi’s orphan drugs to the domestic market. Sobi is a biopharmaceutical company experiencing rapid growth with its innovative treatments for rare diseases. Its main products include “Empaveli,” the first C3 protein-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH), and “Doptelet,” an oral thrombopoietin receptor agonist (TPO-RA) for the treatment of adults with immune thrombocytopenia (ITP), as well as “Kineret” for rheumatoid arthritis, “Gamifant” for hemophagocytic lymphohistiocytosis, and “Vonjo” for myelofibrosis with thrombocytopenia.